OKLAHOMA CITY, May 19 /PRNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc. (OTC Pink Sheets: PDRX), a publicly held corporation, today announced a new trade division, TriMarc Laboratories. The new division will be marketing branded pharmaceutical products to the healthcare industry.
"The TriMarc Laboratories Division was formed with growth opportunities in mind," stated Dr. Robert D. Holsey, President and CEO of PD-Rx Pharmaceuticals. The new division will be offering exclusively licensed and patented pharmaceutical products to an ever-growing healthcare market. With several new products in research and development, TriMarc's current negotiations will lead to rapid growth through co-marketing programs with larger pharmaceutical marketing firms.
ABOUT THE COMPANY
PD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers, and healthcare providers as a progressive and responsive practice.
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic conditions and factors affecting the industry.
PD-Rx Pharmaceuticals, Inc.
CONTACT: Jack L. McCall, EVP & COO of PD-Rx Pharmaceuticals, Inc.,+1-405-942-3040, or email@example.com